计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Nelotanserin is a potent 5-HT 2A inverse agonist, a moderately potent 5-HT 2C partial inverse agonist and a weak 5-HT 2B inverse agonist, with IC 50 s of 1.7, 79, 791 nM in IP accumulation assays, respectively.
In Vitro
Results from IP accumulation assays suggest that Nelotanserin is a potent 5-HT 2A full inverse agonist (IC 50 =1.7 nM), a moderately potent 5-HT 2C partial inverse agonist (IC 50 =79 nM) (maximal response was 62% of the response obtained for the reference inverse agonist clozapine), and a weak 5-HT 2B inverse agonist (IC 50 =791 nM). Nelotanserin displays high affinity for recombinant human 5-HT 2A receptors (K i =0.35 nM), moderate affinity for human 5-HT 2C receptors (K i =100 nM), and low affinity for human 5-HT 2B receptors (2000 nM) stably expressed in HEK293 cells. The results suggest that Nelotanserin has a 262-fold higher affinity for human 5-HT 2A than 5-HT 2C receptors and a 6610-fold higher affinity for human 5-HT 2A than 5-HT 2B receptors. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Each compound is tested in a minimum of five rats by oral gavage with administration occurring in the middle of the inactive period, 6 h after light onset. The delta power during non-REM sleep (NREMS) is significantly different between all the analogues tested and the vehicle control. Nelotanserin (Compound 39) produces significant increases in delta power that persist for the first 4 h following dosing. Significant differences are found, however, in NREMS bout length. Nelotanserin significantly increases NREMS bout length during the first hour following dosing, and 3 does so during the second hour. In conjunction with this increased NREM bout duration, the number of NREM bouts decrease during the first hour for Nelotanserin (p<0.01) as well as for compound 15 (p<0.05). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:5-HT 2A Receptor 1.7 nM (IC 50 ) 5-HT 2C Receptor 79 nM (IC 50 ) 5-HT 2B Receptor 791 nM (IC 50 )
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 唑类 |
| 亚类(Subclass) | 吡唑类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯基吡唑类 |
| 其他上位类(Alternative Parents) | N-苯脲类 甲氧基苯胺 苯氧基化合物 茴香醚 甲氧基苯 烷基芳基醚 氟苯类 芳基溴化物 芳基氟化物 杂芳族化合物 尿素 氮杂环化合物 羰基化合物 有机氮化合物 有机氧化物 有机溴化物 有机氟化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 芳基醚 - 茴香醚 - 芳香族杂单环化合物 - 芳基溴化物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 苯基化合物 - 羰基 - 乙醚 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 甲氧基苯胺 - 甲氧基苯 - 单环苯基基团 - N-吡咯烷酮 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机硒化合物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 苯酚醚 - 苯氧基化合物 - 苯基吡唑 - 脲 |
| 描述(Description) | 该化合物属于苯基吡唑类有机化合物。这类化合物具有苯基吡唑骨架,即吡唑基团与苯基相连的结构。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 3.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|